PRESS-RELEASE ·Filed Apr 27, 2026
Press release: announcement
Actionable Insight • Neutral
Monitor upcoming 10-Q or 20-F filings for any changes in R&D or G&A spending that may reflect the expanded management role. No immediate trading catalyst present.
Final — all horizons settled through T+60d ⚠ clustered
EVAX ▼ -27.27% at T+60d
NEUTRAL call ✗ call lost -27.27% · α vs SPY -32.05% · entry $4.18 → $3.04
T+1d
+3.35%
call +3.35% · α +3.83%
$4.32
settled 5mo ago
T+5d
+9.33%
call +9.33% · α +8.93%
$4.57
settled 5mo ago
T+20d
-1.67%
call -1.67% · α -6.63%
$4.11
settled 4mo ago
T+60d
-27.27%
call -27.27% · α -32.05%
$3.04
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Evaxion promoted its Chief Scientific Officer, Birgitte Rønø, to also serve as Chief Operating Officer to enhance external engagement and strategic execution. The move reflects internal management restructuring but does not involve new financial or operational data.
Key Facts
- Birgitte Rønø, CSO, promoted to dual role of CSO and COO at Evaxion
- Promotion aims to strengthen external visibility and strategic execution of the AI-Immunology™ platform
- No changes to other executive roles; management team remains intact
- No financial metrics, guidance updates, or material operational changes disclosed
Financial Impact
No immediate financial impact — organizational change without cost or revenue implications disclosed
operating_efficiencymanagement_structure
Risk Factors
- Potential operational disruption during leadership transition, though risk appears low given internal promotion
- Forward-looking statements carry uncertainty regarding future partnerships and platform visibility
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281538 |
36 reports for EVAX
100% Hit rate best @ T+5▲ +22.94%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.56%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.88%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.13%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.13%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.56%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.89%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.89%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.39%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.39%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.29%) |
Showing 10 of 36
US Market Status
Market Open — Closes in 1h 31m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access